Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas

Human Pathology

Volumn 42, Issue 2, 2011, Pages 214-226

  Dobashi, Yoh ^a   Suzuki, Shioto ^b   Kimura, Maiko ^a   Matsubara, Hirochika ^c   Tsubochi, Hiroyoshi ^a,d   Imoto, Issei ^e   Ooi, Akishi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Akt; EGFR; Lung carcinoma; mTOR; p70S6 kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6; S6 KINASE;

ARTICLE; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 78751572648     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.05.025     Document Type: Article

References (35)

1. Sharma S.V., Bell D.W., and Settleman J. Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
2. McDonald J.M., Pelloski C.E., and Ledoux A. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung Clin Cancer Res 14 2008 7832 7837
3. Han S.W., Kim T.Y., and Hwang P.G. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
4. Armengol G., Rojo F., and Castellvi J. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications Cancer Res 67 2007 7551 7555
5. Suzuki S., Igarashi S., and Hanawa M. Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas Mod Pathol 19 2006 986 998
6. Liu L.Z., Zhou X.D., and Qian G. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway Cancer Res 67 2007 6325 6332
7. David O., Jett J., and LeBeau H. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage Clin Cancer Res 10 2004 6865 6871
8. Riemenschneider M.J., Betensky R.A., and Pasedag S.M. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling Cancer Res 66 2006 5618 5623
9. Volarevic S., and Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth Prog Nucleic Acid Res Mol Biol 65 2001 101 127
10. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 2004 564 575
11. Pantuck A.J., Seligson D.B., and Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
12. Vignot S., Faivre S., and Aguirre D. mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 2005 525 537
13. Travis W.D.C.T., Corrin B., Shimosato Y., Brambilla E. In collaboration with L.H. Sobin and Pathologists from 14 Countries. The World Health Organization Histological typing of lung and pleural tumours 3rd ed. 1999 Springer New York
14. Greene F.L., Page D.L., and Fleming I.D. American Joint Committee on Cancer staging manual 6th ed. 2002 Springer Philadelphia (Pa)
15. Dobashi Y., Suzuki S., and Sato E. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors Mod Pathol 22 2009 1328 1340
16. Suzuki S., Dobashi Y., and Sakurai H. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study Cancer 103 2005 1265 1273
17. Dobashi Y., Takei N., and Suzuki S. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules Mod Pathol 17 2004 1497 1505
18. Ooi A., Suzuki S., and Nakazawa K. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma Anticancer Res 29 2009 19 26
19. Wu F., Liu S.Y., and Tao Y.M. Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma Cancer 112 2008 2002 2010
20. Dobashi Y., Suzuki S., and Sugawara H. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors Hum Pathol 38 2007 914 925
21. Hoshino R., Chatani Y., and Yamori T. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors Oncogene 18 1999 813 822
22. Nagai Y., Miyazawa H., and Huqun Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp Cancer Res 65 2005 7276 7282
23. Iwenofu O.H., Lackman R.D., and Staddon A.P. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy Mod Pathol 21 2008 231 237
24. Buck E., Eyzaguirre A., and Brown E. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 5 2006 2676 2684
25. Castellvi J., Garcia A., and Rojo F. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer Cancer 107 2006 1801 1811
26. Otulakowski G., Duan W., and O'Brodovich H. Global and gene-specific translational regulation in rat lung development Am J Respir Cell Mol Biol 2008
27. Hennessy B.T., Smith D.L., and Ram P.T. Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 2005 988 1004
28. Conde E., Angulo B., and Tang M. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling Clin Cancer Res 12 2006 710 717
29. Deeb G., Wang J., and Ramnath N. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry Mod Pathol 17 2004 430 439
30. Gulati N., Karsy M., and Albert L. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility Int J Oncol 35 2009 731 740
31. An J.Y., Kim K.M., and Choi M.G. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer Int J Cancer 2009
32. Demidenko Z.N., Shtutman M., and Blagosklonny M.V. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence Cell Cycle 8 2009 1896 1900
33. Herbert T.P., Fahraeus R., and Prescott A. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E Curr Biol 10 2000 793 796
34. La Monica S., Galetti M., and Alfieri R.R. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines Biochem Pharmacol 78 2009 460 468
35. Tee A.R., and Proud C.G. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling Oncogene 19 2000 3021 3031